PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: SHATTUCK et al.)
Serial No.: 10/646,396) Art Unit: 1653
Filed: August 21, 2003)
For: DEPRESSION GENE) Examiner: Karen C. CARLSON

September 7, 2004

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b)(3)

Sir:

Attached is a list of documents on form PTO-1449 together with copies of each identified document. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 CFR § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicants are in no way making any admission as to prior art status of the listed documents, but are instead submitting the listed documents for the sake of full disclosure under 37 CFR § 1.56.

To the best of the undersigned person's knowledge, this Information Disclosure Statement is being submitted in accordance with 37 CFR § 1.97(b)(3), before the mailing of a first Office action on merits.

It is believed that neither an extension of time, nor payment of any fee is required in connection with this communication. However, if an extension of time and corresponding extension fee, or any other fee is required, such an extension of time is hereby petitioned for and the Commissioner is authorized to charge any fees, or credit any overpayment, to Deposit Account No. 50-1627.

Respectfully submitted,

Jonathan Baker

Registration No. 49,022

PATENT & Prince Application of: SHATTUCK et al.

Serial No.: 10/646,396 Filed: August 21, 2003

Page 2

Intellectual Property Department Myriad Genetics, Inc. 320 Wakara Way Salt Lake City, UT 84108

Telephone: Fax:

801-584-3600

801-883-3871

CERTIFICATE OF EXPRESS MAIL

"Express Mail" mailing label number EV 329263514 US Date of Deposit: September 7, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Michael Moreno

Date

\Barrister\Intellectual Property\Patent Prosecution\1300-1399\1309\1309.05\1309.05\2004-09-02 IDS-COVER MM.doc

ubstitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/646,396

Filing Date August 21, 2003

First Named Inventor Donna SHATTUCK

Group Art Unit 1653

Examiner Name Karen C. CARLSON

Attorney Docket Number 1309.05

	(use as many sheets as neo	essa	ny)
Sheet	1	of	

U.S. PATENT DOCUMENTS						
Examiner Initials'	Cite No.¹	U.S. Patent Docume Number Kind C		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
	_A1	6,291,643		Zou et al.	09-18-2001	
	A2	6,346,607		Wang, Xiaodong	02-12-2002	

1

FOREIGN PATENT DOCUMENTS							
Examiner Initials'	Cite No. ¹	Foreign Patent Documents Office ³ Number ⁴ Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	L _e	
	AA	WO 02/057790	Tartakovsky. Boris	07-25-2002			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, volume-issue number(s), page(s), publisher, city and/or country where published.	T²
	B1	VAUX, David L, et al., "CED-4 – The Third Horseman of Apoptosis", <i>Cell</i> , August 8, 1997; 90:389-390	
	B2	ZOU, Hua, et al., "Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c-Dependent Activation of Caspase-3", <i>Cell</i> , August 8, 1997; 90:405-413	
	В3	LI, Peng, et al., "Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade", <i>Cell</i> , November 14, 1997; 91:479-489	
	B4	YOSHIDA, Hiroki, et al., "Apaf1 Is Required for Mitochondrial Pathways of Apoptosis and Brain Development", <i>Cell</i> , September 18, 1998; 94:739-750	
	B5	ZOU, Hua, et al., "An APAF-1•Cytochrome c Multimeric Complex Is a Functional Apoptosome That Activates Procaspase-9", <i>The Journal of Biological Chemistry</i> , April 23, 1999; 274(17):11549-11556	
	B6	LI, Kang, et al., "Cytochrome c Deficiency Causes Embryonic Lethality and Attenuates Stress-Induced Apoptosis", <i>Cell</i> , May 12, 2000; 101:389-399	
	B7	ACEHAN, Devrim, et al., "Three-Dimensional Structure of the Apoptosome: Implications for Assembly, Procaspase-9 Binding, and Activation", <i>Molecular Cell</i> , February 2002; 9:423-432	
	B8	NESTLER, Eric J., et al., "Neurobiology of Depression", <i>Neuron</i> , March 28, 2002; 34:13-25	
	B9	SHIOZAKI, Eric N., et al., "Oligomerization and activation of caspase-9, induced by Apaf-1 CARD", <i>PNAS</i> , April 2, 2002; 99(7):4197-4202	
	B10	NGUYEN, Jack T., "Direct activation of the apoptosis machinery as a mechanism to target cancer cells", <i>PNAS</i> , June 24, 2003; 100(13):7533-7538	
	B11	BELMOKHTAR, Chafke Ahmed, et al., "Apoptosome-independent Pathway for Apoptosis", <i>The Journal of Biological Chemistry</i> , August 8, 2003; 278(32):29571-29580	
	B12	SANTARELLI, Luca, et al., "Requirement of Hippocampal Neurogenesis for the Behavioral Effects of Antidepressants", <i>Science</i> , August 8, 2003; 301:805-809	

Examiner	Date	
Signature	Considered	